Physician-scientist #NIAID @NIH | #Immunology | #innate immunity | #Immunodeficiency | #Fungi | #Infection | Father | 🇬🇷🇺🇸 | Views are mine, not of US govt
Bethesda, MD, USA
Joined January 2021
- Tweets1K
- Following515
- Followers1.5K
- Likes3.6K
Mihalis Lionakis retweeted
𝘊. 𝘢𝘶𝘳𝘪𝘴, a serious public health threat that may have emerged because of climate change, persists on human skin and inanimate objects, frequently causing difficult-to-control outbreaks in health care facilities. Full review with interactive map: nej.md/3CMj8gT
ALT Figure 1. Geographic Origins of Candida auris and Clinical Cases in the United States. Shown are the areas of the globe in which the five C. auris clades initially arose. The inset shows the number of C. auris clinical cases across the United States from 2013 through 2022 (data are from www.cdc.gov/fungal/candida-auris/tracking-c-auris.html). In South Africa and India, C. auris accounts for up to 25% and 40% of candidemia cases, respectively, in certain health care settings.
Mihalis Lionakis retweeted
Our recent study out today in @PLOSPathogens identified cell type specific immune responses to Candida auris skin infection using single cell transcriptomics. Thank you @LionakisLab, Mihai Netea and Vinod for collaborating in this study !
journals.plos.org/plospathog…
Mihalis Lionakis retweeted
Candida auris
Skin tropism
Drug resistance
Challenging infection control
Persistence at hight temperatures and high saline condition
#IDWeek2024 Dr. Lionakis
Mihalis Lionakis retweeted
We are recruiting! A PhD position is available @LabLeibundgut on Malassezia-host interactions. We are looking for highly motivated, creative and dedicated team player. Please apply before 1st November via our PhD program @MimZurich at mim.ethz.ch/application/appl…
Mihalis Lionakis retweeted
Host-microbe interaction paradigms in acute &recurrent vulvovaginal candidiasis
@jessiemacalpine @LionakisLab review host, microbiome &fungal factors that alter susceptibility to vaginal yeast infections & highlight progress in antifungals & vaccination
cell.com/cell-host-microbe/a…
Mihalis Lionakis retweeted
Reviews on Fungi
Host-microbe interaction paradigms in acute & recurrent vulvovaginal candidiasis
cell.com/cell-host-microbe/a…
Intestinal fungal-host interactions in promoting &maintaining health
cell.com/cell-host-microbe/f…
Immunity to fungi &vaccine considerations
cell.com/cell-host-microbe/f…
Mihalis Lionakis retweeted
Last call: ID Service @MSKCancerCenter is hiring a clinician. Interest in stewardship a plus, not required. Apply via: careers.mskcc.org/vacancies/…
Include CV, cover letter, career statement, and contact info for 3 references. Applications reviewed as they come in through October.
Mihalis Lionakis retweeted
Focus on Fungi: from infections to immunity, inflammation, mycobiota, and AMR with the amazing @slg1717 @gordon_d_brown @DukeHeitman @LionakisLab, Bruce Klein, Petra Bacher. #FungaWeek24 @Cell cell.com/cell/fulltext/S0092…
Mihalis Lionakis retweeted
Check out our new preprint "Non-canonical IL-22 receptor signaling remodels the mucosal barrier during fungal immunosurveillance". Thanks to my collaborators @LionakisLab @slg1717 @Jendzjowsky #Filler-lab
biorxiv.org/content/10.1101/…
Mihalis Lionakis retweeted
FungalDx2024 is an amazing opportunity to learn how we can choose the best diagnostic test to detect a fungal infection, to interpret the results, which antifungal is best to use for treatment, how to choose the best platform in resource-rich vs. -limited clinical environment.
Mihalis Lionakis retweeted
Come work with us @NIAIDNews ! Exciting opportunity to do critical work here.
This Post is from an account that no longer exists. Learn more
Mihalis Lionakis retweeted
Please RT and share! @tmhohl71 @LabLeibundgut @UMOWheelerLab @Swidergall_lab @neil_gow @MRCcmm @slg1717 @gordon_d_brown @Mark_Gresnigt @AltheaCampuzano @LionakisLab @GermHunterMD @ImperialFungal @think_fungus @FungalUganda – at Birmingham, England
Mihalis Lionakis retweeted
To learn more about the NIH-University of Pennsylvania Advanced Scholar Immunology Graduate Program, visit us at NIH GRADUATE & PROFESSIONAL SCHOOL FAIR! #GPFair24
Mihalis Lionakis retweeted
m.youtube.com/watch?v=JJ7vI4…
Just dropping this here. Come see what we are all about! @BethesdaID @Strengthie @NIAIDTraining @JMRocco5 @SeretIDirini @VeroNussenMD @LionakisLab @tarapalmore
Mihalis Lionakis retweeted
ASCI member Michail S. Lionakis @LionakisLab @NIAIDNews in @jclinicalinvest:
BTK drives neutrophil activation for sterilizing antifungal immunity: buff.ly/4eEO1T5
#Immunology #InfectiousDisease
Mihalis Lionakis retweeted
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
Concept by Wyndham Wilson, pre-clinical rationale by Lou Staudt, and study led by @MelanicjMD . Thanks to all patients.
Mihalis Lionakis retweeted
JAK–STAT signaling: A pathway through which cytokines and growth factors affect transcriptional changes important in the development of autoimmunity. nej.md/3xbjhIt
ALT A visual representation of "JAK–STAT signaling."
Mihalis Lionakis retweeted
Congrats to Kelsey and @MACattackLab on this very interesting paper on STAT3 in skin inflammation! Inborn errors of #immunity teach us so much!
rupress.org/jem/article-abst…
Mihalis Lionakis retweeted
Original Article: The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1 nej.md/4bXoKkG
Science behind the Study: JAK Inhibition Immunotherapy for APS-1 nej.md/4cfs5Mv
ALT Interferon-γ–Mediated Responses in Blood from Patients with APS-1.
ALT Survival and Organ Damage among Aire−/−Ifng−/− and Aire−/− Mice with or without Ruxolitinib Treatment.
ALT Ruxolitinib-Induced Remission of Autoimmune Manifestations in Patients 1 and 2.
ALT Ruxolitinib-Induced Remission of Autoimmune Manifestations in Patients 3, 4, and 5.